Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Adavosertib + Irinotecan|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Adavosertib||MK-1775|AZD1775|AZ1775||WEE1 Inhibitor 5||Adavosertib (MK-1775) is a small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity (PMID: 22084170, PMID: 32611648).|
|Irinotecan||Camptosar||CPT-11|Onivyde||TOPO1 inhibitor 8||Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||Adavosertib + Irinotecan||Phase I||Actionable||In a Phase I trial (ADVL1312), the combination of Adavosertib (MK-1775) and Camptosar (irinotecan) demonstrated tolerability and some preliminary efficacy in pediatric patients with advanced solid tumors, including one Ewing sarcoma patient who achieved a partial response for three months, and one patient with ependymoma and one patient with neuroblastoma who demonstrated stable disease over 12 months and 7.5 months, respectively (PMID: 31857431).||31857431|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02095132||Phase Ib/II||Adavosertib + Irinotecan||Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors||Active, not recruiting||USA | CAN||0|
|NCT02906059||Phase I||Adavosertib + Irinotecan||Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer||Completed||USA||0|